Trial | NCT04326283  Report issue

Title

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Sequential Dose-Escalation, Randomized, Active-Controlled, Multi-Center, Phase 1/2a Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of SNR1611 in Patients With Amyotrophic Lateral Sclerosis

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    23
The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.
Trametinib (SNR1611) is a MEK inhibitor that downregulates the MAPK/ERK pathway. In this study, the potential of MAPK/ERK pathway downregulation through trametinib (SNR1611) as a therapeutic treatment for amyotrophic lateral sclerosis (ALS) will be evaluated.
Study Started
Apr 02
2020
Primary Completion
Apr 28
2023
Study Completion
Apr 28
2023
Last Update
May 09
2023

Drug Trametinib (0.5 mg)

0.5 mg/day

  • Other names: Meqsel, SNR1611

Drug Trametinib (1 mg)

1 mg/day

  • Other names: Meqsel, SNR1611

Drug Riluzole (100 mg)

100 mg/day (50 mg twice)

  • Other names: Yooritek

Trametinib (0.5 mg) Experimental

One tablet of trametinib 0.5 mg per day

Trametinib (1 mg) Experimental

Two tablets of trametinib 0.5 mg per day

Riluzole (100 mg) Active Comparator

One tablet of riluzole 50 mg taken twice per day

Criteria 

Main inclusion criteria:

Patients diagnosed as definite, probable or probable-laboratory-supported ALS according to El Escorial Criteria.
Patients of less than 2 years after the onset of ALS.
Patients who meet the criteria of K-ALSFRS-R score and forced vital capacity.

Main exclusion criteria:

Patients with primary lateral sclerosis, progressive muscular atrophy or lower motor neuron disease.
Patients who have history of ALS treatment of edaravone or stem cell therapy within 16 weeks before screening.
Patients who have permanently ceased the administration of riluzole due to lack of tolerability and/or efficacy.
Patients in Class II to IV according to the New York Heart Association functional classification. Patients with myocardial infarction, unstable arrhythmia, and/or significant cardiovascular disease such as unstable angina within 12 weeks before screening.
Patients who do not meet the criteria of laboratory tests and medical/operation history.
No Results Posted